Cassava Sciences Inc. (SAVA)
NASDAQ: SAVA
· Real-Time Price · USD
2.35
-0.06 (-2.49%)
At close: Aug 15, 2025, 3:59 PM
2.37
0.85%
After-hours: Aug 15, 2025, 06:28 PM EDT
Company Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019.
Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Cassava Sciences Inc.
| Country | United States |
| IPO Date | Jul 14, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 30 |
| CEO | Richard Jon Barry |
Contact Details
Address: 7801 North Capital of Texas Highway Austin, Texas United States | |
| Website | https://www.cassavasciences.com |
Stock Details
| Ticker Symbol | SAVA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001069530 |
| CUSIP Number | 14817C107 |
| ISIN Number | US14817C1071 |
| Employer ID | 91-1911336 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard Jon Barry | Chief Executive Officer, President & Director |
| Eric J. Schoen | Chief Financial Officer |
| Dr. Angélique Bordey Ph.D. | Senior Vice President of Neuroscience |
| Dr. George Thornton Ph.D. | Senior Vice President of Technology |
| Dr. Michael Marsman Pharm.D. | Senior Vice President of Regulatory Affairs |
| Freda Nassif | Chief Business Officer & Chief Commercial Officer |
| Jack Moore Ph.D. | Senior Vice President of Clinical Development |
| Jaren Landen | Chief Clinical Development Officer |
| Michael Zamloot | Senior Vice President of Technical Operations |
| R. Christopher Cook J.D. | Chief Operating & Legal Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2025 | 10-Q | Quarterly Report |
| Aug 14, 2025 | 8-K | Current Report |
| Aug 04, 2025 | 8-K | Current Report |
| Jul 29, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jul 16, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jul 16, 2025 | 4 | Filing |
| Jun 30, 2025 | 8-K | Current Report |
| May 27, 2025 | 4 | Filing |
| May 27, 2025 | 4 | Filing |
| May 27, 2025 | 4 | Filing |